Complete Guide to Flutamide Pharmacokinetics
Overview
Flutamide is a Non-steroidal Antiandrogen used in the Oncology / Prostate Cancer therapeutic area. It is indicated for Stage D2 metastatic prostate cancer (combined with LHRH agonist). Interactive PBPK-derived pharmacokinetic simulator for flutamide and its active metabolite 2-OH-flutamide. Based on Sharma et al. (2020) whole-body PBPK model calibrated to Radwanski et al. (1989) human data. Explore CYP1A2-driven metabolism, tissue partition coefficients (Kp prostate/plasma = 2.17), and parent-metabolite PK for prostate cancer dosing (250 mg TID).
Mechanism of Action
Flutamide exerts its pharmacological effect by targeting Androgen Receptor (AR). As a Non-steroidal Antiandrogen, it modulates this target to achieve therapeutic efficacy in Stage D2 metastatic prostate cancer (combined with LHRH agonist). Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PBPK-Derived Parent-Metabolite (1-CMT per species) models for Flutamide:
| Parameter | Value |
|---|---|
| ka | 1.5-2.5 h⁻¹ |
| CL F | 25-35 L/h |
| Vc F | 60-80 L |
| dose | 250 mg TID |
| route | Oral |
| t half | 5-6 hours (flutamide) |
| fm CYP1A2 | 0.90 |
| metabolite | 2-OH-Flutamide |
| Cmax parent | ~800 ng/mL (250 mg dose) |
| Kp prostate | 2.17 (prostate/plasma ratio) |
| Cmax metabolite | ~1500 ng/mL (active metabolite) |
| bioavailability | >85% |
| protein binding | 94-96% |
| t half metabolite | 8-10 hours (2-OH-flutamide) |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Flutamide is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology / Prostate Cancer therapeutic area, for the treatment of Stage D2 metastatic prostate cancer (combined with LHRH agonist), understanding the pharmacokinetics of Flutamide is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Flutamide pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Flutamide PK Simulator
Explore Flutamide pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Flutamide?
The elimination half-life of Flutamide depends on patient-specific factors. Based on published models, the typical half-life is approximately 5-6 hours (flutamide).
How is Flutamide administered?
Flutamide is administered via the Oral route. It is indicated for Stage D2 metastatic prostate cancer (combined with LHRH agonist). As a Non-steroidal Antiandrogen, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Flutamide?
Key pharmacokinetic parameters for Flutamide include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Flutamide dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Flutamide PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.